The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
Fred R Hirsch1, Corey J Langer
1University of Colorado Cancer Center, Department of Medical Oncology/Pathology, Denver 80262, USA.
Abstract:
Research over the past decade has led to an increased understanding of the pathophysiology of lung cancer. The HER2/neu receptor is a member of the ErbB family of signaling-transduction receptors and appears to play a major role in the development of lung cancer as well as many other solid tumors. HER2/neu is overexpressed in 16% to 57% of patients with non-small cell lung cancer (NSCLC) and studies have shown that HER2/neu overexpression imparts a poor prognosis in both resected and advanced NSCLC, as it does in breast cancer. Trastuzumab, a humanized monoclonal antibody that recognizes the HER2/neu protein receptor, has been approved by the US Food and Drug Administration for patients with HER2/neu-positive metastatic breast cancer. In NSCLC preclinical studies, marked synergistic growth inhibition occurred when standard cytotoxic chemotherapy was combined with trastuzumab in HER2/neu-expressing cell lines. In the clinical setting, trastuzumab has proven safe and feasible in combination with cytotoxic chemotherapy in both single-institution and multi-institutional cooperative group studies. Unlike the experience in advanced breast cancer, cardiac toxicity is a marginal concern in this population. However, to date, clinical studies with trastuzumab in patients with NSCLC have not shown a demonstrable advantage for the majority of patients.
Insights
Trastuzumab shows potential in treating non-small cell lung cancer (NSCLC) by targeting HER2/neu overexpression. While safe with chemotherapy, current clinical trials indicate limited patient benefit.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- HER2/neu receptor tyrosine kinase overexpression is implicated in non-small cell lung cancer (NSCLC) pathogenesis.
- HER2/neu overexpression correlates with poor prognosis in NSCLC, similar to its role in breast cancer.
- Trastuzumab, an anti-HER2/neu monoclonal antibody, is FDA-approved for HER2/neu-positive metastatic breast cancer.
Purpose of the Study:
- To evaluate the efficacy and safety of trastuzumab in combination with chemotherapy for HER2/neu-expressing NSCLC.
- To explore the potential of targeting HER2/neu as a therapeutic strategy in NSCLC.
Main Methods:
- Preclinical studies demonstrated synergistic growth inhibition with trastuzumab and chemotherapy in HER2/neu-expressing NSCLC cell lines.
- Clinical studies assessed the safety and feasibility of combining trastuzumab with standard cytotoxic chemotherapy in NSCLC patients.
Main Results:
- Trastuzumab combined with chemotherapy was found to be safe and feasible in clinical settings for NSCLC.
- Cardiac toxicity was a minimal concern in NSCLC patients treated with trastuzumab.
- Despite preclinical promise and safety, clinical trials have not yet demonstrated a significant survival advantage for most NSCLC patients.
Conclusions:
- Trastuzumab is a safe and feasible treatment option in combination with chemotherapy for NSCLC patients with HER2/neu overexpression.
- Further research is needed to identify NSCLC patient subgroups who may benefit from trastuzumab therapy.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:39lncRNA - Long Non-coding RNAs